LoneStar Heart Receives European Approval For Algisyl-LVR® Hydrogel Implant
Implantable Gel May Revolutionize the Treatment of Patients Who Lose the Ability to Pump Blood Efficiently to the Body LAGUNA HILLS, Calif., Oct. 1, 2014 /PRNewswire/ — LoneStar Heart, Inc. today announced that it received the CE Mark (Conformite Europeene) for its Algisyl-LVR® hydrogel implant, the company’s lead product for the treatment of advanced heart…